Not a good buy right now for an impatient trader: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and fundamentals/Street revisions remain negative.
Oversold conditions (RSI_6 ~25.7) suggest a bounce is possible, but it’s counter-trend and not supported by strong catalysts before earnings.
Options positioning is aggressively call-skewed, but extremely high implied volatility implies expensive premiums and elevated event risk into the 2026-02-25 earnings.
Net: Avoid new longs at this moment; only consider if it reclaims the pivot (~2.365) and holds above it, signaling trend stabilization.
Volatility: 30D IV ~121.5% with IV percentile ~94% = options are pricing very large moves; premiums are expensive.
Activity: Today’s volume 1,309 with strong vs average (62.6) and open interest elevated (today vs OI avg 82.1) = traders actively positioning, likely ahead of earnings.
Takeaway: Options market implies “big move” risk; call-skew supports upside attempts, but high IV also signals the market expects turbulence and makes risk/reward for fresh long entries less attractive at-the-moment.
Technical Summary
Sell
8
Buy
3
Positive Catalysts
can produce a short-term rebound if buyers defend that level.
Neutral/Negative Catalysts
Core business headwinds: pharmacy partner pushback, contract renegotiations, pricing pressure, and volume declines (per Jefferies downgrade commentary).
Hedge fund flow: “Hedge Funds are Selling” with selling amount up ~1160% last quarter (bearish institutional signal).
Earnings/event risk: elevated IV suggests the market expects a large move; downside gap risk remains material if results/guidance disappoint.
Technical trend remains bearish (below major moving averages); rallies may be sold until trend flips.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $196.0M, +0.40% YoY (very low growth).
Profitability: Net income $1.12M, -71.78% YoY; EPS down to ~0 (-100% YoY) = significant earnings deterioration.
Margins: Gross margin 82.22%, down 3.32% YoY = margin compression trend is negative.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent Street trend: broadly negative revisions with multiple price-target cuts across firms.
Key changes:
Jefferies (2026-01-22): Downgrade to Hold from Buy; PT cut to $2.75 from $5.25 (strongly negative signal, cites core segment pressure and slow recovery).
BofA (2026-01-05): Kept Underperform; PT cut to $2.60 from $3 (bearish).
Morgan Stanley (2025-12-18): Equal Weight; PT cut to $4 from $5 (neutral but trimming).
Citi (2026-01-09): Kept Buy; PT cut to $4.50 from $5 (still constructive but lowering expectations).
JPMorgan / TD Cowen: Still positive ratings but both cut PTs (constructive longer-term, cautious near-term).
Wall Street pros vs cons:
Pros: some bulls see optionality from new offerings/partnerships and longer-dated benefits (potentially 2027+).
Cons: near-term fundamentals pressured, ecosystem reimbursement/pharmacy closures impacting volumes, and expectation resets evidenced by PT cuts/downgrades.
Politicians/influential trading: No recent congress trading data available; insider trend noted as neutral.
People Also Watch
Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.46 USD with a low forecast of 2.6 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.46 USD with a low forecast of 2.6 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
2 Sell
Hold
Current: 2.210
Low
2.6
Averages
4.46
High
7
Current: 2.210
Low
2.6
Averages
4.46
High
7
Jefferies
Buy
to
Hold
downgrade
AI Analysis
2026-01-22
Reason
Jefferies
Price Target
AI Analysis
2026-01-22
downgrade
Buy
to
Hold
Reason
Jefferies downgraded GoodRx to Hold from Buy with a price target of $2.75, down from $5.25. The company's prescription discount segment, which is nearly 70% of its revenue, is struggling with declining volumes and pricing pressure amid contract renegotiations and pharmacy partner pushback, the analyst tells investors in a research note. Jefferies says the closures of 800 pharmacy locations from June to July last year, following the Rite Aid bankruptcy, significantly impacted GoodRx's business. A recovery will take time and be slow to ramp, the firm contends.
Citi
Buy
maintain
$5
2026-01-09
Reason
Citi
Price Target
$5
2026-01-09
maintain
Buy
Reason
Citi lowered the firm's price target on GoodRx to $4.50 from $5 and keeps a Buy rating on the shares as part of the firm's 2026 outlook note on the health tech and distribution group. 2025 proved to be another challenging year for health tech, with nearly one-third of the group down greater than 25%, but the firm is "cautiously optimistic" looking ahead to 2026, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GDRX
